GSK Extends China Vaccine Deal with Zhifei to 2034
Ticker: GLAXF · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, vaccines, china, extension
TL;DR
GSK inks Shingrix deal extension to 2034 in China with Zhifei, eyes Arexvy collab.
AI Summary
GSK plc announced on December 5, 2024, that it has revised and extended its strategic vaccine collaboration with Zhifei in China. The agreement for Shingrix has been extended to 2034, and GSK has granted Zhifei expanded exclusive rights to explore collaboration on Arexvy.
Why It Matters
This extension secures GSK's market presence for key vaccines in China, a significant growth market, and strengthens its partnership with Zhifei.
Risk Assessment
Risk Level: low — This is an extension of an existing collaboration and does not appear to involve new significant financial commitments or risks.
Key Players & Entities
- GSK plc (company) — Registrant and collaborator
- Zhifei (company) — Collaborator in China
- Shingrix (product) — Vaccine with extended collaboration
- Arexvy (product) — Vaccine for potential collaboration
- 2034 (date) — End date for Shingrix collaboration extension
- December 5, 2024 (date) — Date of announcement
FAQ
What is the duration of the extended Shingrix collaboration in China?
The Shingrix collaboration has been extended to 2034.
Who is GSK's partner in this revised vaccine collaboration in China?
GSK's partner is Zhifei.
What other vaccine is mentioned for potential collaboration with Zhifei?
Arexvy is mentioned for potential collaboration.
When was this revised collaboration announced?
The announcement was made on December 5, 2024.
What specific rights has GSK granted Zhifei regarding Arexvy?
GSK has granted Zhifei expanded exclusive rights to explore collaboration with Zhifei on Arexvy.
Filing Stats: 1,736 words · 7 min read · ~6 pages · Grade level 11.5 · Accepted 2024-12-05 06:03:59
Filing Documents
- a8828o.htm (6-K) — 49KB
- 0001654954-24-015167.txt ( ) — 50KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 05, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc